Project summary

OXC-101 (Karonudib)OXC-201 (OGG1 Inhibitor)
What?Treating cancer by taking advantage of the high load of endogenous DNA damage and oxidative stress in cancer cells.Treating diseases caused by inflammation and fibrosis, e.g. pulmonary fibrosis, via DNA damage response pathways.
Problem today?Cancers are heterogenous both between cancer indications and within same indication. Resistance development. Tolerability.Treatment for these diseases are unsatisfactory. Risk for major loss of organ function, increased mortality and high costs for society.
Oxcia’s solutionOXC-101 ensures that cancer cells cannot repair the DNA and oxygen damage, so the cancer cell cannot grow and subsequently dies.OGG1 inhibitor stops the inflammatory response as well as the fibrosis production and hence the disease.
BenefitsTargets cancer cell phenotype, rather than oncogene or tumour suppressor gene. Healthy cells are not affected. Makes cold tumours hot. Low resistance development.Potential to cure the disease, not only addressing the symptoms.

Project pipeline

Two ongoing phase I studies with completion in 2022

Clinical phasePhase IPhase I
TitleMTH1, A Phase I,
Study on Tumours Inhibition,
First in Human, First in Class
A phase 1 study in patients with hematological malignancies to evaluate safety, tolerability and efficacy of Karonudib